TL;DR — Antioxidant defense needs three layers: GSH substrate (GlyNAC), gene induction (sulforaphane), and redox recycling (R-ALA). No single compound covers all three. Run the AM choreography for 24 weeks; track GSH and hs-CRP at baseline, week 12, and week 24.
Why this stack exists
Most people take one antioxidant and wonder why oxidative stressAn imbalance between reactive oxygen species (free radicals) produced by metabolism and the antioxidant systems that neutralize them. Full glossary → markers don't move. The NRF2 pathway isn't a single switch — it's a three-layer system:
| Layer | Compound | Role | Analogy |
|---|---|---|---|
| Substrate | GlyNAC | Glycine + cysteine → GSH pool | Fuel tank |
| Signal | Sulforaphane | NRF2A protein that turns on 200+ antioxidant and detox genes when activated. Full glossary → → 200+ genes (GCLC, GCLM, NQO1, HO-1) | Amplifier |
| Recycle | R-ALA | GSSG → GSH; vit C/E recycling | Recycler |
← Swipe for more columns →
Gap analysis — what breaks when you use only one:
- NAC without NRF2 induction → under-expressed synthesis enzymes
- Sulforaphane without substrate → induced genes starve for building blocks
- Either without R-ALA → GSSG accumulates; oxidized glutathioneYour body's most abundant internal antioxidant, made from glycine, cysteine, and glutamate. Full glossary → can't cycle back
Suggested visual
Suggested visual: Three-layer shield diagram — inner (GSH pool), middle (NRF2 gene battery), outer (R-ALA redox cycle). Arrows showing ROS interception at each layer.
Mechanistic synergyWhen two compounds together produce greater effect than either alone. Full glossary → map
`
ROS attack
↓
[GlyNAC] → GSH direct neutralization
↓ (if overwhelmed)
[Sulforaphane] → NRF2 → ↑ GCLC, GCLM, NQO1, HO-1, GST
↓
[R-ALA] → GSSG → GSH regeneration + vit C/E recycling
↓
Reduced oxidative damage → Genomic stability + Mito protection + ↓ Inflammation
`
Hallmarks addressed: Genomic instability · Mitochondrial dysfunction · Loss of proteostasis · Chronic inflammation — with zero mechanistic redundancy between legs.
Evidence per leg
| Compound | Tier | Key human data |
|---|---|---|
| GlyNAC | A | GSH restoration, ↓ oxidative stress (PMID 33783984) |
| Sulforaphane | A | NRF2 target gene induction (PMID 38772511) |
| R-ALA | B | Mitochondrial redox support; GSH recycling well-characterized |
Combination logic: No single RCT tested this exact triad. Synergy is mechanistically complementary with independent Tier A/B legs — TNiC grades the stack architecture as Tier A for NRF2 pathway coverage.
Individual legs carry Tier A/B evidence. Combined stack addresses 4 hallmarks with zero mechanistic redundancy.
Is the NRF2 triad right for you?
GSH below 5.0 OR hs-CRP above 1.0 OR high oxidative stress lifestyle (smoker, heavy alcohol, chronic poor sleep)?
node | On chemotherapy or nitroglycerin?
redflag | STOP — physician clearance required before any antioxidant stack
Start full triad with AM choreography → 24-week commitment
node | Already taking NAC or glycine alone?
Upgrade to full GlyNAC pair + add sulforaphane at week 2
Run 8 weeks sleep + exercise → retest hs-CRP before supplement spend
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
AM choreography (non-negotiable spacing)
| Step | Time | Compound | Dose | Notes |
|---|---|---|---|---|
| 1 | Wake + water | GlyNAC | 600 mg gly + 600 mg NAC | Empty stomach OK |
| 2 | +15–30 min | Sulforaphane | 10–35 mg glucoraphanin | Active myrosinase preferred |
| 3 | Breakfast | R-ALA | 300–600 mg | With food; R-enantiomer only |
← Swipe for more columns →
Why spacing matters: Sulforaphane after GlyNAC ensures substrate is available when NRF2 upregulates GCLC/GCLM. R-ALA with fat-containing breakfast improves absorption and handles the GSSG load from overnight metabolism.
Day-one setup (15 minutes)
- Prewrite your AM sequence on a phone note: GlyNAC → timer 20 min → sulforaphane → breakfast + R-ALA
- Pre-sort weekly pill organizers by day — triad compliance fails on travel days, not intention days
- Log baseline labs before dose 1: GSH + hs-CRP minimum viable panel
- Set calendar alerts for week 12 and 24 blood draws
- Pair with GlyNAC compound guide for single-leg deep dive
Biomarker targets
| Marker | Baseline | 12 wk | 24 wk | Stack success signal |
|---|---|---|---|---|
| GSH | Log | ↑ toward 5.0+ | Optimal range | Primary |
| hs-CRP | Log | ↓ | <1.0 mg/L | Secondary |
| oxLDL | Log | ↓ | <60 U/L | Vascular oxidative stress |
| 8-OHdG | Optional | ↓ trend | — | DNA damage proxy |
← Swipe for more columns →
GSH (μmol/L)
<5.0
hs-CRP (mg/L)
>1.0
Subjective energy
5–6/10
Recovery after exercise
Poor
GSH (μmol/L)
5.0–8.5
hs-CRP (mg/L)
<1.0
Subjective energy
7–8/10
Recovery after exercise
Moderate+
Red flags and contraindications
Hard stops — do not run this stack without clearance
- Active chemotherapy or radiation — antioxidant stacks may interfere with treatment intent
- NAC + nitroglycerin — potential dangerous hypotension interaction
- High-dose R-ALA + diabetes medications — hypoglycemia risk; monitor glucose weekly for 4 weeks
- Hypothyroid on levothyroxine — NAC may affect T4 conversion at high doses; check TSH at 12 weeks
- No biomarker movement at 24 weeks — don't escalate doses blindly; audit compliance and sleep first
Soft cautions
Sulforaphane can cause mild GI upset — take with a small meal if step 2 on empty stomach fails. R-ALA has a distinct sulfur taste; splitting dose AM/PM is acceptable if breakfast dose causes nausea.
Stack variants by budget
| Tier | Components | Monthly est. | Coverage |
|---|---|---|---|
| Starter | GlyNAC only | $ | Substrate layer — upgrade path clear |
| Core | GlyNAC + sulforaphane | $$ | Substrate + signal |
| Full triad | All three legs | $$$ | Complete NRF2 architecture |
| Elite | Triad + NAD+ Mito Stack | $$$$ | Mito + antioxidant orthogonal coverage |
← Swipe for more columns →
When to add the NAD+ Mito Stack
Add NMN after 8–12 weeks of triad compliance if: energy plateaus despite GSH normalization, NAD+ index below 80, or mitochondrial hallmark is your primary target. Run stacks sequentially — not all on day one.
Personal results template
My NRF2 Triad log
| Date | Week | GlyNAC ✓ | Sulforaphane ✓ | R-ALA ✓ | GSH | hs-CRP | Energy | Notes |
|---|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | — | — | Baseline |
| YYYY-MM-DD | 12 | ✓ | ✓ | ✓ | — | — | — | Mid-point |
| YYYY-MM-DD | 24 | ✓ | ✓ | ✓ | — | — | — | Primary endpoint |
← Swipe for more columns →
Compliance target: ≥85% daily adherence (allow 1 missed day per week without resetting clock)
Response criteria: - Win: GSH optimal OR hs-CRP ↓≥30% + energy ↑2 points - Iterate: Flat GSH at week 12 with perfect compliance → verify sulforaphane myrosinase activity - Stop signal: Glucose dropping symptomatically on R-ALA → reduce dose, monitor
Enable NRF2 Defense stack
Pre-built stack with synergy scoring and contraindication checks.
Open Stack ArchitectReferences
- Kumar P et al. GlyNAC supplementation improves glutathione deficiency in aging humans. J Gerontol A Biol Sci Med Sci (2021). PMID 33783984
- See PMID registry. Sulforaphane upregulates NRF2 and NQO1 in CKD patients. Free Radic Biol Med (2024). PMID 38772511
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.